Showing results (1341-1350 of 1,799) with videos related to

Sort By:
Pageof 180
Mabs|March 29, 2012
The Cabilly patents: status quo and relevance for antibody companiesUlrich Storz
Mabs|April 26, 2012
Insights from Fc receptor biology: a route to improved antibody reagentsJenny M Woof
Mabs|April 26, 2012
Lepidopteran cells, an alternative for the production of recombinant antibodies?Martine Cérutti, Josée Golay
Mabs|April 26, 2012
Marketed therapeutic antibodies compendiumJanice M Reichert
Mabs|April 26, 2012
The birth pangs of monoclonal antibody therapeutics: the failure and legacy of CentoxinLara Marks
Mabs|April 26, 2012
Galactosylation variations in marketed therapeutic antibodiesT Shantha Raju, Robert E Jordan
Mabs|April 26, 2012
Impact of linker and conjugation chemistry on antigen binding, Fc receptor binding and thermal stability of model antibody-drug conjugatesMauro Acchione, Hyewon Kwon, Claudia M Jochheim, et al.
Mabs|June 7, 2012
Increased serum clearance of oligomannose species present on a human IgG1 moleculeLeslie Alessandri, David Ouellette, Aima Acquah, et al.
Mabs|September 19, 2015
Development of human-like scFv-Fc antibodies neutralizing Botulinum toxin serotype BChristine Rasetti-Escargueil, Arnaud Avril, Siham Chahboun, et al.
Mabs|April 1, 2016
Preclinical pharmacokinetics of MHAA4549A, a human monoclonal antibody to influenza A virus, and the prediction of its efficacious clinical dose for the treatment of patients hospitalized with influenza APriyanka Gupta, Amrita V Kamath, Summer Park, et al.
Pageof 180